Experts discuss clinical, pathologic, and genomic features of Burkitt lymphoma in adults, as well as standard and emerging treatment options for this patient population.
Nearly half of all relapses occurred within the first month of CAR-T infusion.
Peripheral T-cell lymphoma is characterized by extensive epigenetic dysregulation.
Loncastuximab tesirine is an antibody drug conjugate composed of a humanized monoclonal antibody directed against human CD19 and conjugated through a linker to a pyrrolobenzodiazepine dimer cytotoxin.
Investigators summarize current literature surrounding the treatment of NLPHL and discuss treatment considerations for 2 clinical cases.
Researchers report on results with CAR-T therapy in real-world populations of patients with ALL or NHL.
A retrospective analysis highlights the reasons for discontinuation of ibrutinib among patients with mantle cell lymphoma.
Adults treated for Hodgkin lymphoma have an increased risk of death from heart disease, interstitial lung disease, infections, and adverse effects of therapy.
Depending on the type and stage of lymphoma, physicians may choose to avoid having their patients undergo radiation therapy for fear of potential toxic effects in organs.
Small studies, the absence of subtypes, and a historical lack of genetic information has stopped past studies from triggering meaningful public health change, a review asserts.
Exposure to doxorubicin during treatment for DLBCL was linked to a higher risk for cardiovascular diseases, highlighting the need for early cardiac surveillance.
Among patients with early-stage, favorable Hodgkin lymphoma, treatment regimens with conventional chemotherapy may be effective in a subset of patients.
Tazemetostat yielded clinically meaningful, durable responses and was well tolerated in patients with relapsed or refractory follicular lymphoma.
Responses were also observed in patients previously treated with HDAC or mTOR inhibitors.
Combined modality therapy for early-stage favorable HL yielded excellent outcomes and limited excess radiation doses to organs at risk.
The expanded approval was based on data from the randomized, open-label, phase 3 KEYNOTE-204 trial.
Findings suggest that brentuximab vedotin plus nivolumab was well tolerated and active in older patients with previously untreated HL with comorbidities.
A case report detailed reinfection with SARS-CoV-2 in an immunocompromised patient with Waldenström macroglobulinemia.
Pregnant patients with non-Hodgkin lymphoma may be able to receive CHOP-like chemotherapy during pregnancy with some risks.
Although 1 in 1000 lymphoma diagnoses occurs in pregnancy, literature on best practices for treatment in this patient group is limited.
In a phase 2 trial, obinutuzumab added to induction therapy showed promising activity and tolerability for transplant-eligible mantle cell lymphoma.
Investigators characterized the risks of stage- and cause-specific mortality among patients with classical Hodgkin lymphoma treated with chemotherapy.
Among a subset of patients with previously treated Waldenström macroglobulinemia, ibrutinib is highly active and may lead to long-term disease control.
The signaling pathways detected may shed light on new treatment strategies.
Investigators assessed safety and efficacy outcomes of lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphoma.
In Japan, insurance coverage for breast implantation is limited to procedures using Allergen-manufactured products.
Characterizing gene expression profiles of FL cells from intrafollicular and extrafollicular regions may help to identify future therapeutic targets.
Researchers reviewed the clinical/pathologic aspects of HSTCL and summarized the latest molecular studies and potential novel therapeutic targets.
Delayed evaluation could decrease unnecessary invasive tests.
Using a grading system for skin flare reactions increases potential for continuing administration of mogamulizumab despite the occurrence of this adverse effect.
Investigators measured ixazomib, dexamethasone, and rituximab combination treatment among patients with treatment-naive Waldenström macroglobulinemia.
Researchers assessed diagnosis, risk-stratification, and management of 3 distinct subgroups of primary cutaneous lymphomas.
Novel immunotherapies and small molecule pathway inhibitors are transforming the standard of care for some of the most challenging lymphoma subtypes.
A small study suggests that low-dose pembrolizumab or nivolumab may be effective and safe for the treatment of r/r classical Hodgkin lymphoma.
Neurotoxicity is a common AE associated with CAR-T administration, but there are limited data characterizing it among patients with LBCL who received axi-cel.
Lipid changes in the B-cell lymphoma microenvironment may influence natural killer cell metabolism and function.
In this study, researchers determined that the quantity and quality of discussions regarding survivorship and late effects of treatment between AYA lymphoma survivors and their oncologists is improving, but survivorship information is still lacking.
While the rate of certain HIV-linked non-Hodgkin lymphomas has declined since the introduction of ART, the incidence of Burkitt lymphoma has remained steady.
Researchers studied clinical characteristics linked to overall survival and lymphoma-specific survival in patients with plasmablastic lymphoma.
Researchers evaluated data from younger patients with Waldenström macroglobulinemia to determine features that predict outcomes in this patient population.
The treatment reduced hospital stay but not neutropenia duration or infection rate.
All responders were found to have the same structural rearrangements.
Researchers at UT MD Anderson Cancer Center in Houston present tools that support patient adherence to acalabrutinb in the setting of MCL.
TP53 missense mutations through routine analysis is needed for patients with mantle cell lymphoma.
Study results suggest allogeneic SCT as standard consolidation therapy in pediatric patients with progression during frontline therapy or relapse of a CD3-positive ALCL.
Researchers in the Netherlands conducted HOVON-84 to determine what benefit, if any, early rituximab intensification had in adult patients with untreated DLBCL.
Among patients with T cell lymphoblastic leukemia, event-free survival at 24 months is a strong surrogate endpoint for long-term survival.
The overall response rate was 95.9%, with 100% of patients in the TN group and 93.9% of patients in the RR group responding.
Tafasitamab-cxix is a humanized Fc-modified monoclonal antibody that targets CD19 antigen on the surface of pre-B and mature B lymphocytes and on several B-cell malignancies, including DLBCL.
CD30 CAR-T cell treatment after lymphodepletion may produce antitumor activity without significant toxicity in relapsed or refractory Hodgkin lymphoma.
Researchers for the RELEVANCE study measured MRD in a subset of patients to compare the molecular response of patients receiving R2 vs R-chemo.